BCL2 and B-cell chronic lymphocytic leukemia: At the same time, new targeted therapies have been developed and introduced in the treatment of patients with CLL, i.e., BTK and BCL2 inhibitors, hitting the Achille’s heel of the disease and making CLL an ideal candidate for applying the principles of precision medicine (3, 4).